Iteos Therapeutics to Highlight Inupadenant Preclinical, Translational, and Phase 2 a2a-005 Clinical Trial Data in 2L Nsclc at Esmo Immuno-Oncology Congress
iteos therapeutics將在Esmo免疫腫瘤學大會上重點展示Inupadenant的臨床前、轉化和2期a2a-005臨床試驗數據在2L Nsclc中
Iteos Therapeutics to Highlight Inupadenant Preclinical, Translational, and Phase 2 a2a-005 Clinical Trial Data in 2L Nsclc at Esmo Immuno-Oncology Congress
iteos therapeutics將在Esmo免疫腫瘤學大會上重點展示Inupadenant的臨床前、轉化和2期a2a-005臨床試驗數據在2L Nsclc中
譯文內容由第三人軟體翻譯。
使用瀏覽器的分享功能,分享給你的好友吧